Abstract
Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Cephalosporins / pharmacology*
-
Clostridioides difficile / classification
-
Clostridioides difficile / drug effects*
-
Clostridioides difficile / genetics
-
Microbial Sensitivity Tests
-
Penicillanic Acid / analogs & derivatives*
-
Penicillanic Acid / pharmacology
-
Phylogeny
-
Tazobactam
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
ceftolozane
-
Penicillanic Acid
-
Tazobactam